SIRT5 and thyroid cancer: LncRNA GLTC acts as a binding partner of LDHA to inhibit the regulatory effect of SIRT5 on LDHA by competitively binding LDHA with SIRT5, promoting the succinylation of LDHA at the lysine 155 site, thereby promoting the enzymatic activity of LDHA, and thus promoting the progression of thyroid cancer [85].